FDA is encouraging the brand and generic drug industries to come up with a unified proposal for the development of generic abuse-deterrent opioid products.
Douglas Throckmorton, deputy director for regulatory programs in FDA’s Center for Drug Evaluation and Research, advocated the approach at the...